UNSPSC 51372902: Clonitazene

This classification denotes an opioid receptor agonist with the molecular formula C20H23ClN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S90R21A2V2, chemically known as 1h-benzeimidazole-1-ethanamine, 2-((4-chlorophenyl)methyl)-n,n-diethyl-5-nitro- but generally known as clonitazene, which bears US NIH Compound Identifier 62528. European Medicines Agency schedules Clonitazene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06731MIG.

UNSPSC 51372902 Clonitazene, a Commodity code, does not align with the state and local procurement opportunities recently tagged under it. The three opportunities on record involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations involve clonitazene, an opioid analgesic with limited legitimate civilian use. The code shows little relevant recent procurement activity grounded in the commodity's actual market scope.

Seminole County's IFB60459723LAS (posted June 30, 2026, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for community health initiatives, with quarterly deliveries to the Seminole County Community Health Building and a two-year term with one-year renewal option. The Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities, with pricing evaluation weighted 75 percent on competitiveness. These opportunities reflect health-system procurement for harm-reduction supplies, prescription fulfillment innovation, and broad pharmaceutical supply rather than procurement of clonitazene specifically. The code tagging appears misaligned with actual commodity scope.